Redeye updates on Better Collective following preliminary Q3-results which were significantly weaker...
The company's focus on profitability, cash flow and safeguarding its core service operations has sta...
Q3: 3% org. sales growth, 6% adj. EBITA growth, strong cash flow '24e-'26e adj.
Redeye lowers its fair value range following a reconsideration of its financial estimates (following...
Net sales of EUR 112m was well above our expectation (EUR 91m) in Q3.
Redeye comments on the CESTAFOUR and CAPAFOUR results published today.
Redeye sustains its positive view of CombinedX despite a weak Q3 report, leading to cuts in our 2024...
Loihde reports its Q3 business report on October 30th.
Consti’s Q3/24 figures were in line with our estimates.
Redeye comments on Nitro Games' Q3 2024 report, which was stronger than expected, both in terms of s...
Enea’s report aligned with Redeye’s estimates (RRe) on a constant currency basis.
Gapwaves announced a supply agreement and joint development with Valeo (previously undisclosed Europ...
Vitrolife delivered a consecutive positive organic growth recovery with 7% organic growth in constan...
Redeye makes slight adjustments to its forecasts following Xbrane's Q3 report, which indicated conti...
The company's Q3 net sales and adjusted EBIT were close to LSEG Data & Analytics consensus.
Ahead of Cibus' Q3 report, we include the acquisition of eight properties in Denmark and Finland, an...
Redeye maintains its fair value range for Sleep Cycle following the Q3 2024 quarterly report, which ...
During Q3, Svedberg Group once again demonstrated the strength of its risk-balanced portfolio.
Redeye retains its Base Case following a solid Q3 report, slightly beating our forecasts on EBITA.
Redeye thinks that Lagercrantz reported another stable quarter in a challenging market.